Medtech manufacturer KMM lands growth investment from RS2 Healthcare Partners
What's the deal? KMM Group, a Hatboro, Pennsylvania-based precision contract manufacturer, has received a growth equity investment from Boston private equity firm RS2 Healthcare Partners, with Riverside PartnersDealroom has a profile for this one. Try Dealroom → also participating. The deal, announced July 27, 2026, brings a leadership shake-up alongside the capital.
What does KMM do? It is a vertically integrated manufacturer of complex, tight-tolerance components for the medical device industry and other demanding markets. The company positions itself as a specialist in "failure-intolerant" engineering challenges.
New leadership: KMM named J. Mark King president and chief executive officer. King previously led Tegra MedicalDealroom has a profile for this one. Try Dealroom →, a medical device contract manufacturer and former RS2 portfolio company, and Clinical InnovationsDealroom has a profile for this one. Try Dealroom →, and has held roles at Baxter Healthcare, Cardinal Health, and Johnson & Johnson.
What happens to the founders? Co-founder John Shegda becomes chief technology officer, leading engineering and technology strategy. Co-founder Eric Wilhelm takes on executive vice president, business transformation and organisational capability, overseeing operations and scalable growth.
Why now? The changes are framed around KMM's "next phase of growth." King said he wants to "expand the Company's capabilities and further strengthen its position as a premier contract manufacturer for medtech and other end markets."
Investor view: "KMM is an exceptional company, with an excellent reputation in the marketplace, highly specialized capabilities, a blue chip customer base, and an extremely dedicated group of employees," said Craig Stern, co-managing partner at RS2 Healthcare Partners.
The signal: The deal reflects private equity's continued appetite for founder-owned medtech suppliers, pairing capital with veteran operators to scale niche manufacturing. RS2's reuse of King, who ran an earlier portfolio company, underscores how buyout firms lean on trusted executives to run repeat plays in the sector.
Read more: Morningstar
